Companies · Biotechnology

Paratus Diagnostics, LLC

San Marcos · Biotechnology

Diligence memoA one-page analyst read on Paratus Diagnostics, LLC — recommendation, valuation, rhythm, risks.
$8.1M
Total raised · real
3
Rounds
1.9×
Latest step-up
Top 49%
Sector rank · raised
Series A
Latest stage · inferred · Fri Nov 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Paratus Diagnostics, LLC looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.89× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era.
  • Within the normal band (89% of peer median) for its niche.
Dormant
  • Last raise 7.6 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Paratus Diagnostics, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
10.5 yr record
Peak capital year was 2018 with $5.2M across 1 filings.
Market position
ahead of 52% of Biotechnology peers
Capital scale is ahead of 52% of Biotechnology peers; modeled value is above 71% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2018: $5.2M across 1 filings.
  • Largest single filing was $5.2M on 2018-11-16.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Paratus Diagnostics, LLC is one of 4291 Biotechnology companies tracked from San Marcos. By capital raised it ranks mid-pack (ahead of 52% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

medical-devices

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
43
Investors (latest)
2018-11-16
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2015-12-22 Raised $100K (real) Modeled valuation $5.5M (est)$100K$5.5MPre-Seed2015Seed · 2016-07-11 Raised $2.8M (real) Modeled valuation $124M (est)$2.8M$124MSeed2016Series A · 2018-11-16 Raised $5.2M (real) Modeled valuation $188M (est)$5.2M$188MSeries A2018+$2.8M+$5.2MCumulative $8.1M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$100K · 2015
Seed$2.8M · 2016
Series A$5.2M · 2018

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$188.2M
Base estimate est.
$5.7M
Conservative case
$1.0B
Upside case
$23.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $5.5M · 2015-12-222015Seed · modeled $124.3M · 2016-07-11Series A · modeled $188.2M · 2018-11-162018
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
7.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
17 mo
Avg between rounds
$2.8M/yr
Capital velocity
10.5 yr
On record since
2015
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.1× above median
This company$8.1M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.0× of median
This company$5.2M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 2.9× above median
This company$188.2M
Sector median$64.2M

Raised more than 52% of sector peers (real $). Modeled value above 71% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #89 of 157.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Cynvec LLC · Series A Raised $17.4M · modeled $542.3M (est)Anthera Pharmaceuticals Inc · Series A Raised $15.0M · modeled $542.3M (est)Bio-Dent, LTD. LLC · Series A Raised $15.0M · modeled $542.3M (est)Biothera Holding Corp. · Series A Raised $16.2M · modeled $529.3M (est)Limelight Bio, Inc. · Series A Raised $14.0M · modeled $506.2M (est)Overture Life, Inc. · Series A Raised $13.6M · modeled $491.7M (est)TAI Diagnostics, Inc. · Series A Raised $21.1M · modeled $463.8M (est)Occulo Holdings LLC · Series A Raised $12.8M · modeled $462.7M (est)Agilis Biotherapeutics, Inc. · Series A Raised $25.7M · modeled $458.0M (est)CAMBRIDGE EPIGENETIX Ltd · Series A Raised $12.3M · modeled $444.4M (est)Genten Therapeutics, Inc. · Series A Raised $12.0M · modeled $433.8M (est)LTC BioSciences, Inc · Series A Raised $12.0M · modeled $433.8M (est)Paratus Diagnostics, LLC (this company) Raised $8.1M · modeled $188.2M (est)Paratus Diagnostics, LLC
CompanyStageRaised · realValue · estvs peer med.
Cynvec LLCSeries A$17.4M$542.3M2.57×
Anthera Pharmaceuticals IncSeries A$15.0M$542.3M2.57×
Bio-Dent, LTD. LLCSeries A$15.0M$542.3M2.57×
Biothera Holding Corp.Series A$16.2M$529.3M2.51×
Limelight Bio, Inc.Series A$14.0M$506.2M2.40×
Overture Life, Inc.Series A$13.6M$491.7M2.33×
TAI Diagnostics, Inc.Series A$21.1M$463.8M2.20×
Occulo Holdings LLCSeries A$12.8M$462.7M2.19×
Agilis Biotherapeutics, Inc.Series A$25.7M$458.0M2.17×
CAMBRIDGE EPIGENETIX LtdSeries A$12.3M$444.4M2.11×
Genten Therapeutics, Inc.Series A$12.0M$433.8M2.06×
LTC BioSciences, IncSeries A$12.0M$433.8M2.06×
Paratus Diagnostics, LLC this companySeries A$8.1M$188.2M0.89×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$100K2015-12-22$556K$5.5M85%
Seed$2.8M2016-07-11$14.0M$124.3M85%
Series A$5.2M2018-11-16$23.7M$188.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$100K2015-12-22
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Seed$2.8M2016-07-11
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 28.0× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 506(c)).
    • 43 investors on this round.
  3. Series A$5.2M2018-11-16
    • Raised again after 28 mo — slower than the ~14 mo sector norm.
    • Round 1.9× larger than the prior — scaling up.
    • 43 investors on this round.
Intelligence
2020 ~Q2
Modeled next raise · ~17mo cadence
$9.7M
Modeled next size est.range $6.3M$15.5M
1.9×
Last step-up
$2.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Gene C. Betts2018-11
John Carrano2015-12
John C. Carrano2016-07
Michael C. Matula2018-11
Phil C. Jones2018-11
Robert C. Donnelly2018-11
Roland Q Schneider2018-11
Wayne Q Radwanski2018-11
Registry & provenance

Paratus Diagnostics, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1661922
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Inmune Bio, Inc.BiotechnologySeries A$8.0M$169.9Msame sector · same stage
Asylia Therapeutics, Inc.BiotechnologySeries A$8.2M$218.5Msame sector · same stage
Proteogenix IncBiotechnologySeries A$8.0M$144.6Msame sector · same stage
Kraig Biocraft Laboratories, IncBiotechnologySeries A$8.0M$233.0Msame sector · same stage
Cytocom Inc.BiotechnologySeries A$8.3M$167.3Msame sector · same stage
Cerus Endovascular LtdBiotechnologySeries A$8.3M$213.7Msame sector · same stage
PharmaTher Holdings Ltd.BiotechnologySeries A$7.9M$156.4Msame sector · same stage
pHLIP, Inc.BiotechnologySeries A$7.9M$159.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Ascendant Diagnostics LLCBiotechnologyPre-Seed$26.3M85%
Cardio Diagnostics Inc.BiotechnologySeries A$94.1M85%
Lucid Diagnostics Inc.BiotechnologySeries B$132.1M85%
TAI Diagnostics, Inc.BiotechnologySeries A$463.8M85%
Brava Diagnostics, Inc.BiotechnologySeed$11.1M85%
Cardio Diagnostics Holdings, Inc.BiotechnologyPre-Seed$5.9M85%
Biomark Diagnostics Inc.BiotechnologySeed$8.0M85%
Avant Diagnostics, IncBiotechnologySeed$51.7M84%
Frequently asked
How much funding has Paratus Diagnostics, LLC raised?
Paratus Diagnostics, LLC has raised approximately $8.1M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Paratus Diagnostics, LLC's estimated valuation?
Provath's modeled valuation for Paratus Diagnostics, LLC is approximately $188.2M (modeled range $5.7M–$1.0B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Paratus Diagnostics, LLC at?
Paratus Diagnostics, LLC's latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Nov 16.
What does Paratus Diagnostics, LLC do and where is it based?
Paratus Diagnostics, LLC operates in the Biotechnology sector, based in San Marcos.
Explore related

See where Paratus Diagnostics, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Paratus Diagnostics, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.